Literature DB >> 7641510

Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis.

A Ravelli1, S Viola, B Ramenghi, G Di Fuccia, N Ruperto, L Zonta, A Martini.   

Abstract

In juvenile chronic arthritis (JCA) the indices of disease activity, such as joint swelling, pain, tenderness, and limitation of motion, may poorly correlate with the degree of functional impairment. Since the improvement of functional capacity is one of the main objectives of treatment, we evaluated the effect of methotrexate (MTX) in 29 children with JCA by assessing both the articular indices and a functional status measure. After 6 months of therapy, 15 of the 29 patients had a significant (> or = 50%) reduction in the number of joints with active arthritis and/or the articular severity score and were then judged as responders, while 14 did not respond to MTX. In the responder group, the median functional index score decreased from 17 (range: 13-27) at baseline to 13 (range: 13-15) at 6 months (p < 0.001); the median score of the non-responder group was 20 both at baseline and at 6 months (ranges: 14-27, and 13-36, respectively). These results show an improvement of functional impairment in those patients who respond to MTX according to the conventional indices of articular inflammation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641510     DOI: 10.1007/bf02208347

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  Therapeutic criteria in rheumatoid arthritis.

Authors:  O STEINBROCKER; C H TRAEGER; R C BATTERMAN
Journal:  J Am Med Assoc       Date:  1949-06-25

2.  Methotrexate hepatotoxic effects in children with juvenile rheumatoid arthritis.

Authors:  A Martini; A Ravelli; S Viola; R G Burgio
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

3.  Development of a disability measurement tool for juvenile rheumatoid arthritis. The Juvenile Arthritis Functional Assessment Report for Children and their Parents.

Authors:  S Howe; J Levinson; E Shear; S Hartner; G McGirr; M Schulte; D Lovell
Journal:  Arthritis Rheum       Date:  1991-07

4.  Evaluation of a functional index in rheumatoid arthritis.

Authors:  P Lee; M K Jasani; W C Dick; W W Buchanan
Journal:  Scand J Rheumatol       Date:  1973       Impact factor: 3.641

5.  Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires.

Authors:  P Tugwell; C Bombardier; W W Buchanan; C Goldsmith; E Grace; K J Bennett; H J Williams; M Egger; G S Alarcon; M Guttadauria
Journal:  Arch Intern Med       Date:  1990-01

6.  Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis.

Authors:  C D Rose; B H Singsen; A H Eichenfield; D P Goldsmith; B H Athreya
Journal:  J Pediatr       Date:  1990-10       Impact factor: 4.406

7.  Low-dose methotrexate in systemic onset juvenile chronic arthritis.

Authors:  M Speckmaier; J Findeisen; P Woo; A Hall; J A Sills; T Price; P Hollingworth; A Craft; B M Ansell
Journal:  Clin Exp Rheumatol       Date:  1989 Nov-Dec       Impact factor: 4.473

8.  Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis.

Authors:  A Ravelli; G Di Fuccia; M Molinaro; B Ramenghi; L Zonta; M B Regazzi; A Martini
Journal:  J Rheumatol       Date:  1993-09       Impact factor: 4.666

9.  Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype.

Authors:  F Halle; A M Prieur
Journal:  Clin Exp Rheumatol       Date:  1991 May-Jun       Impact factor: 4.473

10.  Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study.

Authors:  H Truckenbrodt; R Häfner
Journal:  Arthritis Rheum       Date:  1986-06
View more
  3 in total

Review 1.  [The treatment of juvenile rheumatism: pharmacotherapy].

Authors:  F Weller; H-I Huppertz
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

Review 2.  Use of methotrexate in juvenile idiopathic arthritis.

Authors:  A V Ramanan; P Whitworth; E M Baildam
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

3.  Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis.

Authors:  Elena Palmisani; Nicoletta Solari; Angela Pistorio; Nicolino Ruperto; Clara Malattia; Stefania Viola; Antonella Buoncompagni; Anna Loy; Alberto Martini; Angelo Ravelli
Journal:  Pediatr Rheumatol Online J       Date:  2007-12-11       Impact factor: 3.054

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.